Ready-to-use Dynabeads will allow you to optimize ex vivo T cell activation and proliferation in translational research, while preserving T cell viability and optimal immune function. Simultaneous signaling to TCR/CD3 and CD28 triggers a physiological activation and expansion of human T cells. You can also stimulate and expand human antigen–specific T cell lines or clones using Dynabeads Human T-Activator CD3/CD28/CD137
This simple, efficient and consistent technology out-performs and replaces traditional home-brew methods for generic activation based on antigen-presenting cells (APCs), mitogens (e.g. ConA, PHA), soluble/plate-bound antibodies, or chemical activators, and is well documented in published literature. Expansion and re-infusion of genetically engineered T cells has the potential to revolutionize the treatment of leukemia and related blood cancers. A clinical research grade version is also available, allowing you to move from mouse studies to clinical research using the same technology platform.
Which human T Cell activation/expansion product is right for you?
|Activation and expansion of polyclonal T cells||Activation and expansion of regulatory T cells||Expansion of antigen-specific T cells||Isolation and expansion of polyclonal T cells||cGMP-grade beads for isolation and expansion of polyclonal T cells|
|Dynabeads Human Treg Expander||Dynabeads Human T-Activator CD3/CD28/CD137
||Dynabeads Human T-Expander CD3/CD28||Dynabeads CD3/CD28 CTS™|
|Research grade||Research grade||Research grade||Research grade||Research-grade version of the cGMP-grade product||For research use or non-commercial manufacturing of cell-based products for clinical research|
|Starting samples||Pure T cells isolated from any sample||Pure regulatory T cells isolated from any sample||T cell lines or T cell clones||Pure T cells isolated from any sample, preferably from cryopreserved human PBMC||Cryopreserved human PBMC obtained from leukapheresis product|
|No. of cells processed||4 x 107 cells /
|5 x 106 cells / mL beads||5 x 106 cells / mL beads||3.3 x 107 cells / mL beads||1.6 x 108 cells / mL beads|
|Bead:T cell ratio for activation
|Applications||Short-term activation or expansion of polyclonal T cells without the need for feeder cells for use in e.g., transfection/ transduction, T cell receptor signaling, proteomics.||Short-term activation or expansion of pre-isolated regulatory
T cells without the need for feeder cells e.g., for use in flow cytomery, MLR, proteomics, gene expression.
|Expansion of antigen-specific
T cells without the use of feeder cells e.g., for use in flow cytometry, phenotyping, adoptive transfer.
|Isolation and expansion of CD3+
T cells, or expansion of pre-isolated T cells or T cell subsets without the need for feeder cells.
|Isolation and expansion of CD3+
T cells or expansion of pre-isolated T cells or T cell subsets without the need for feeder cells.
|Shelf life from production date||2 years||2 years||2 years||2 years||2 years|
|Required materials||Magnets: magnets+ rIL-2 (for expansion)||Magnets: magnets+ rIL-2 (for expansion)||Magnets: magnets
|Magnets: DynaMag CTS Magnet (Cat. No. 12102),
or visit magnets
|Magnets: DynaMag CTS Magnet (Cat. No. 12102), or visit magnets+ rIL-2|
The references listed below are among the many published papers documenting the performance of the Dynabeads technology for T cell activation and expansion:
- Porter, DL et al. (2011) Chimeric Antigen Receptor–Modified T Cells in Chronic Lymphoid Leukemia. N Engl J Med 365:725-733.
- Kalos M et al (2011) T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia. Sci Transl Med 3:95ra73
- Berger C et al (2003) CD28 costimulation and immunoaffinity-based selection efficiently generate primary gene-modified T cells for adoptive immunotherapy. Blood 101:476–484.
- Bonyhadi M et al (2005) In vitro engagement of CD3 and CD28 corrects T cell defects in chronic lymphocytic leukemia. J Immunol 174:2366–2375.
- Hami L et al (2003) Comparison of a static process and a bioreactor-based process for the GMP manufacture of autologous Xcellerated T cells for clinical trials. BioProcessing Journal Vol. 2 No. 6.
- Levine BL et al. (2002) Adoptive transfer of costimulated CD4+ T cells induces expansion of peripheral T cells and decreases CCR5 expression in HIV infection. Nat Med 8:47–53.
- Godfrey WR et al (2004) In vitro expanded human CD4+CD25+ T regulatory cells can markedly inhibit allogeneic dendritic cell stimulated MLR cultures. Blood 104:453–461.
- Coito S et al. (2004) Retrovirus-mediated gene transfer in human primary T lymphocytes induces an activation-and transduction/selection-dependent TCRBV repertoire skewing of gene-modified cells. Stem Cells Dev 13:71–81.
- Rapoport AP et al (2005) Restoration of immunity in lymphopenic individuals with cancer by vaccination and adoptive T-cell transfer. Nat Med 11:1162–1163.
For Research Use Only. Not for use in diagnostic procedures.